Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Payables: 2013-2025

Historic Payables for Ocular Therapeutix (OCUL) over the last 12 years, with Sep 2025 value amounting to $6.3 million.

  • Ocular Therapeutix's Payables rose 56.46% to $6.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $21.0 million, marking a year-over-year increase of 13.05%. This contributed to the annual value of $4.2 million for FY2024, which is 4.85% down from last year.
  • According to the latest figures from Q3 2025, Ocular Therapeutix's Payables is $6.3 million, which was up 6.30% from $5.9 million recorded in Q2 2025.
  • Ocular Therapeutix's 5-year Payables high stood at $12.4 million for Q1 2021, and its period low was $3.4 million during Q1 2022.
  • In the last 3 years, Ocular Therapeutix's Payables had a median value of $4.6 million in 2025 and averaged $5.0 million.
  • As far as peak fluctuations go, Ocular Therapeutix's Payables skyrocketed by 153.25% in 2021, and later crashed by 72.51% in 2022.
  • Quarterly analysis of 5 years shows Ocular Therapeutix's Payables stood at $4.6 million in 2021, then climbed by 11.56% to $5.1 million in 2022, then declined by 14.33% to $4.4 million in 2023, then dropped by 4.85% to $4.2 million in 2024, then soared by 56.46% to $6.3 million in 2025.
  • Its last three reported values are $6.3 million in Q3 2025, $5.9 million for Q2 2025, and $4.6 million during Q1 2025.